Drugs / BTX-1188
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05144334 | Jan 2022 → Sep 2023 | acute myeloid leukemia, non-Hodgkin lymphoma | Biotheryx, Inc. | Terminated | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-26 | Biotheryx, Inc. | Biotheryx to Present Preclinical Data for Its Dual Protein Degrader BTX-1188 at the 2022 American Society of Clinical Oncology Annual Meeting biotheryx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BTX-1188 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05144334 ↗ |
| Route | Oral | “BTX-1188 administered orally” NCT05144334 ↗ |